Last updated: 4 July 2020 at 1:06pm EST

Global Strategic Fund, L.P.... Net Worth




The estimated Net Worth of Global Strategic Fund, L.P.... is at least $525 Tausend dollars as of 1 April 2019. Global P owns over 50,000 units of Precision BioSciences stock worth over $525,000 and over the last 6 years Global sold DTIL stock worth over $0.

Global P DTIL stock SEC Form 4 insiders trading

Global has made over 1 trades of the Precision BioSciences stock since 2019, according to the Form 4 filled with the SEC. Most recently Global bought 50,000 units of DTIL stock worth $800,000 on 1 April 2019.

The largest trade Global's ever made was buying 50,000 units of Precision BioSciences stock on 1 April 2019 worth over $800,000. On average, Global trades about 50,000 units every 0 days since 2019. As of 1 April 2019 Global still owns at least 50,000 units of Precision BioSciences stock.

You can see the complete history of Global P stock trades at the bottom of the page.



Insiders trading at Precision BioSciences

Over the last 6 years, insiders at Precision BioSciences have traded over $352,500 worth of Precision BioSciences stock and bought 224,670 units worth $1,909,002 . The most active insiders traders include Raymond F Schinazi, Llc Fmr und Michael Amoroso. On average, Precision BioSciences executives and independent directors trade stock every 22 days with the average trade being worth of $357,735. The most recent stock trade was executed by Dario Scimeca on 7 June 2024, trading 301 units of DTIL stock currently worth $3,161.



What does Precision BioSciences do?

Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.



What does Precision BioSciences's logo look like?

Precision BioSciences, Inc. logo

Complete history of Global P stock trades at Precision BioSciences

Datum
#
Unternehmen
Insider
Trans.
Transaktion
Anzahl der Aktien Preis je Aktie Gesamtpreis Anzahl der Aktien nach Quelle
1 Apr 2019 Global Strategic Fund, L.P....
Kauf 50,000 $16.00 $800,000
1 Apr 2019
50,000


Precision BioSciences executives and stock owners

Precision BioSciences executives and other stock owners filed with the SEC include: